Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease

An 8-month prospective pilot study

Ali A. Rizvi, Angelo Maria Patti, Rosaria Vincenza Giglio, Dragana Nikolic, Antonella Amato, Noor Al-Busaidi, Khalid Al-Rasadi, Maurizio Soresi, Maciej Banach, Giuseppe Montalto, Manfredi Rizzo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode real-time ultrasound were assessed at baseline and 4 and 8 months.Results: Glycated hemoglobin reduced significantly in both groups. No significant changes were found in body weight, waist circumference and lipids. Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).Conclusion: Eight months of liraglutide use in patients with T2DM and NAFLD significantly reduced carotid IMT, a surrogate marker of atherosclerosis, independently of glucometabolic changes.

Original languageEnglish
Pages (from-to)1391-1397
Number of pages7
JournalExpert Opinion on Biological Therapy
Volume15
Issue number10
DOIs
Publication statusPublished - Oct 3 2015

Fingerprint

Carotid Intima-Media Thickness
Medical problems
Liver
Type 2 Diabetes Mellitus
Prospective Studies
Atherosclerosis
Metformin
Glycosylated Hemoglobin A
Waist Circumference
Liraglutide
Non-alcoholic Fatty Liver Disease
Research Design
Biomarkers
Ultrasonics
Body Weight
Outcome Assessment (Health Care)
Lipids

Keywords

  • carotid intima-media thickness
  • liraglutide
  • non-alcoholic fatty liver disease
  • type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease : An 8-month prospective pilot study. / Rizvi, Ali A.; Patti, Angelo Maria; Giglio, Rosaria Vincenza; Nikolic, Dragana; Amato, Antonella; Al-Busaidi, Noor; Al-Rasadi, Khalid; Soresi, Maurizio; Banach, Maciej; Montalto, Giuseppe; Rizzo, Manfredi.

In: Expert Opinion on Biological Therapy, Vol. 15, No. 10, 03.10.2015, p. 1391-1397.

Research output: Contribution to journalArticle

Rizvi, Ali A. ; Patti, Angelo Maria ; Giglio, Rosaria Vincenza ; Nikolic, Dragana ; Amato, Antonella ; Al-Busaidi, Noor ; Al-Rasadi, Khalid ; Soresi, Maurizio ; Banach, Maciej ; Montalto, Giuseppe ; Rizzo, Manfredi. / Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease : An 8-month prospective pilot study. In: Expert Opinion on Biological Therapy. 2015 ; Vol. 15, No. 10. pp. 1391-1397.
@article{5a8dd30659174bbc9efd2727aabab19a,
title = "Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pilot study",
abstract = "Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode real-time ultrasound were assessed at baseline and 4 and 8 months.Results: Glycated hemoglobin reduced significantly in both groups. No significant changes were found in body weight, waist circumference and lipids. Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).Conclusion: Eight months of liraglutide use in patients with T2DM and NAFLD significantly reduced carotid IMT, a surrogate marker of atherosclerosis, independently of glucometabolic changes.",
keywords = "carotid intima-media thickness, liraglutide, non-alcoholic fatty liver disease, type 2 diabetes",
author = "Rizvi, {Ali A.} and Patti, {Angelo Maria} and Giglio, {Rosaria Vincenza} and Dragana Nikolic and Antonella Amato and Noor Al-Busaidi and Khalid Al-Rasadi and Maurizio Soresi and Maciej Banach and Giuseppe Montalto and Manfredi Rizzo",
year = "2015",
month = "10",
day = "3",
doi = "10.1517/14712598.2015.1067299",
language = "English",
volume = "15",
pages = "1391--1397",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease

T2 - An 8-month prospective pilot study

AU - Rizvi, Ali A.

AU - Patti, Angelo Maria

AU - Giglio, Rosaria Vincenza

AU - Nikolic, Dragana

AU - Amato, Antonella

AU - Al-Busaidi, Noor

AU - Al-Rasadi, Khalid

AU - Soresi, Maurizio

AU - Banach, Maciej

AU - Montalto, Giuseppe

AU - Rizzo, Manfredi

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode real-time ultrasound were assessed at baseline and 4 and 8 months.Results: Glycated hemoglobin reduced significantly in both groups. No significant changes were found in body weight, waist circumference and lipids. Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).Conclusion: Eight months of liraglutide use in patients with T2DM and NAFLD significantly reduced carotid IMT, a surrogate marker of atherosclerosis, independently of glucometabolic changes.

AB - Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode real-time ultrasound were assessed at baseline and 4 and 8 months.Results: Glycated hemoglobin reduced significantly in both groups. No significant changes were found in body weight, waist circumference and lipids. Carotid IMT decreased significantly in the T2DM patients with NAFLD (from 0.96 ± 0.27 to 0.82 ± 0.17 to 0.85 ± 0.12 mm, p = 0.0325), but not in the T2DM patients without NAFLD (from 0.91 ± 0.23 to 0.88 ± 0.17 to 0.85 ± 0.15 mm, p = 0.4473).Conclusion: Eight months of liraglutide use in patients with T2DM and NAFLD significantly reduced carotid IMT, a surrogate marker of atherosclerosis, independently of glucometabolic changes.

KW - carotid intima-media thickness

KW - liraglutide

KW - non-alcoholic fatty liver disease

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84942029356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942029356&partnerID=8YFLogxK

U2 - 10.1517/14712598.2015.1067299

DO - 10.1517/14712598.2015.1067299

M3 - Article

VL - 15

SP - 1391

EP - 1397

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 10

ER -